The Deal Register
Database › M&A › Essa Pharma Inc. to Adjourn Special Meeting to September 29, 2025

M&A

Essa Pharma Inc. to Adjourn Special Meeting to September 29, 2025

Lane
M&A
Announced
10 Sep 2025
Province
British Columbia
Industry
Healthcare & life sciences
Status
Announced
What the filing says
ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that the Board of Directors of the Company has approved an adjournment of the special meeting of the holders of common shares of the Company ("Common Shares" and the holders of such Common Shares, the "Shareholders"), optionholders and warrantholders (the "Special Meeting") scheduled to occur on September 10, 2025 to consider and approve the Company's previously announced transaction with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding…
Source

Compiled from public filings, court documents, exchange bulletins and issuer releases. Figures are as disclosed and are not independently verified.

Not financial, investment, legal or tax advice, and not an offer to buy or sell any security. Verify everything before you transact.

The Deal Register · Archive · Subscribe